Advancing Clinical Research in Primary Glomerular Diseases (UM1) | Apply Online

Opportunity Summary:

The grant opportunity "Advancing Clinical Research in Primary Glomerular Diseases (UM1)" (Funding Opportunity Number RFA-DK-12-014) is a National Institutes of Health (NIH) cooperative agreement aimed at speeding up translational and clinical research that directly supports therapeutic development for primary glomerular diseases. In practical terms, the announcement is focused on moving promising ideas toward real-world treatments by funding studies that can clarify disease mechanisms in patients, identify and validate clinical or biological markers, and generate evidence needed to design or run clinical trials. The FOA places particular emphasis on chronic forms of four primary glomerular diseases that often lead to persistent proteinuria and progressive kidney damage: minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), immunoglobulin A nephropathy (IgAN), and idiopathic membranous nephropathy (IMN). The overall intent is to build a stronger pipeline from patient-oriented science to therapies that can prevent progression, reduce relapses, and improve long-term kidney outcomes.

This opportunity is offered under a cooperative agreement mechanism (UM1), which typically means the funded projects are expected to involve substantial scientific or programmatic involvement from NIH staff compared with a standard research project grant. While applicants still propose and lead their own research programs, a UM1 generally signals closer coordination with NIH priorities, potential collaboration across sites or networks, and an expectation that the work will be organized in a way that supports shared goals such as harmonized protocols, common data elements, and outputs that are immediately useful for therapeutic development. The activity category is listed under health, and the award is administered through the NIH institute responsible for this area, reflected by the CFDA number 93.847 (Diabetes, Digestive, and Kidney Diseases Extramural Research).

In terms of scale, the FOA anticipated approximately five awards with an estimated total funding level of $3,000,000. No cost sharing or matching requirement was indicated, which lowers a common barrier for applicants by allowing budgets to be driven by the science rather than by required institutional contributions. The opportunity was posted on September 7, 2012, with an original and current closing date of February 27, 2013, and an archive date of March 30, 2013, meaning it was a time-limited solicitation rather than an ongoing program announcement.

Eligibility is broad across U.S.-based organizations and includes many categories that commonly participate in NIH-funded research. Eligible applicants include public and state-controlled institutions of higher education, private institutions of higher education, nonprofits (both 501(c)(3) and non-501(c)(3)), small businesses, and for-profit organizations other than small businesses. It also includes a wide range of governmental entities such as city or township governments, county governments, state governments, special district governments, and eligible housing authorities, as well as tribal governments and tribal organizations. The FOA explicitly notes additional eligible applicant types such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, tribally controlled colleges and universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and faith-based or community-based organizations, along with regional organizations and U.S. territories or possessions. Foreign institutions are not eligible to apply, and non-domestic components of U.S. organizations are not eligible; the FOA also states that foreign components, as defined by NIH policy, are not allowed, reinforcing that the research activities supported through this mechanism must remain domestic.

For applicants, the practical takeaway is that NIH was seeking clinically grounded, translational research programs centered on chronic primary glomerular diseases, structured in a way that could realistically accelerate therapy development. That usually implies work such as developing or validating endpoints that matter in trials (for example, kidney function trajectories or proteinuria-based outcomes), identifying patient subgroups most likely to respond to certain interventions, using patient biospecimens to discover and qualify biomarkers, and building clinical research infrastructure that can support multicenter observational studies or early-phase interventional studies. The focus on chronic forms of MCD, FSGS, IgAN, and IMN suggests an emphasis on patients with ongoing disease activity, relapse-prone courses, or progressive disease where new treatments and better trial tools are urgently needed.

The administering agency is NIH, and the full announcement was made available through the NIH grants portal (link provided in the source). For technical issues accessing the announcement, the contact listed is the NIH Office of Extramural Research (OER) webmaster at FBOWebmaster@OD.NIH.GOV, which is a standard point of contact for problems with the online listing rather than a scientific program contact for questions about fit or scope.

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Food and Nutrition Health

Next opportunity: Attwaters Prairie Chicken Breeding Facility

Previous opportunity: Notice of Intent to Award

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for RFA DK 12 014

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (RFA DK 12 014) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "RFA DK 12 014", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.